Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
United States: American Society for Pharmacology and Experimental Therapeutics
Erscheinungsjahr
2004
Quelle
EZB-FREE-00999 freely available EZB journals
Beschreibungen/Notizen
The mammalian mismatch repair (MMR) system has been implicated in activation of the G 2 checkpoint induced by methylating agents. In an attempt to identify the signaling events accompanying this phenomenon, we
studied the response of MMR-proficient and -deficient cells to treatment with the methylating agent temozolomide (TMZ). At
low TMZ concentrations, MMR-proficient cells were growth-inhibited, arrested in G 2 /M, and proceeded to apoptosis after the second post-treatment cell cycle. These events were accompanied by activation of
the ATM and ATR kinases, and phosphorylation of Chk1, Chk2, and p53. ATM was activated later than ATR and was dispensable
for phosphorylation of Chk1, Chk2, and p53 on Ser15 and for triggering of the G 2 /M arrest. However, it conferred protection against cell growth inhibition induced by TMZ. ATR was activated earlier than
ATM and was required for an efficient phosphorylation of Chk1 and p53 on Ser15. Moreover, abrogation of ATR function attenuated
the TMZ-induced G 2 /M arrest and increased drug-induced cytotoxicity. Treatment of MMR-deficient cells with low TMZ concentrations failed to
activate ATM and ATR and to cause phosphorylation of Chk1, Chk2, and p53, as well as G 2 /M arrest and apoptosis. However, all these events occurred in MMR-deficient cells exposed to high TMZ concentrations, albeit
with faster kinetics. These results demonstrate that TMZ treatment activates ATM- and ATR-dependent signaling pathways and
that this process is absolutely dependent on functional MMR only at low drug concentrations.